Pasithea Therapeutics Warrants
KTTAW
5 hedge funds and large institutions have $27K invested in Pasithea Therapeutics Warrants in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
150% more funds holding
Funds holding: 2 → 5 (+3)
1.36% more ownership
Funds ownership: 4.86% → 6.22% (+1.4%)
44% less capital invested
Capital invested by funds: $48.7K → $27K (-$21.7K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$6 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3 |
Top Sellers
KTTAW Hedge Fund Activity: Q2 2023 in Review
5 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q2 2023, worth a combined $27K — down 44% from $48.7K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KTTAW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $6.
- 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q2 2023, up from 2 in Q1 2023.
- Funds reported $27K of Pasithea Therapeutics Warrants stock for Q2 2023, down 44% quarter-over-quarter.
- 3 funds opened new Pasithea Therapeutics Warrants positions in Q2 2023 and 0 closed out, a net change of +3 holders.
- The largest Pasithea Therapeutics Warrants buyer in Q2 2023 was Clear Street, an estimated $6 added.
Based on aggregated 13F filings for Q2 2023.